Press releases
-
-
-
-
-
-
Internal link ProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private Placement
-
-
-
-
-
-
Internal link ProQR Highlights Pipeline Expansion and Multiple Upcoming Clinical Catalysts at Investor and Analyst Event
-
-
Internal link ProQR to Host Virtual Investor and Analyst Event Highlighting Pipeline on April 8, 2026
-
-
-
Internal link ProQR Announces Planned Changes to Board Composition
-
Internal link ProQR Announces Encouraging AX-0810 Phase 1 Safety and PK Data, Development Candidate Selections, and 2026 Outlook
-
Internal link ProQR Therapeutics Added to NASDAQ Biotechnology Index
-
Internal link ProQR annonce la publication dans Nature Medicine des données du QR-110 pour l’amaurose congénitale de Leber 10
-
Internal link ProQR Announces Publication in Nature Medicine of QR-110 Data for Leber’s Congenital Amaurosis 10
-
-
Internal link ProQR Receives € 4.7 million in Innovation Credit from Dutch Government for QR-110 for LCA10
-
Internal link ProQR Announces Clearance of IND to Start Clinical Trial of QR-421a in Usher Syndrome Type 2 Patients
-